This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "osteoporosis_bone_resorption#Increased Osteoclastic Bone Resorption"). Conforming nodes should substitute the disorder-specific driver of the remodeling imbalance: estrogen deficiency in postmenopausal osteoporosis, Wnt/Dkk1 suppression in glucocorticoid-induced osteoporosis, and LRP5/WNT1 or COL1A1/COL1A2 variants in monogenic low-bone-mass disorders.
The "Endosteal Vascular Niche Dysfunction" node is a deliberately separate, EMERGING upstream arm (hypothesis group endosteal_vascular_niche_model). It is not part of the settled RANKL/Wnt chain and should not be treated as such: a disorder node should declare conformance to it only when there is a specific endothelial or vascular-smooth-muscle lesion in bone, not merely because the disorder features low bone mass.
Endosteal Vascular Niche Contribution to Bone Turnover
endosteal_vascular_niche_model
EMERGING
Evidence: 3
Evidence balance
3 support
An emerging model in which endothelial cells and vascular smooth muscle cells of the endosteal compartment are themselves regulators of bone mass, rather than passive supporting tissue, so that a primary vascular lesion can drive remodeling imbalance and low bone mass. The evidence base is a cross-species single-cell map of the murine endosteal compartment integrated with a human bone mineral density GWAS, functional validation in over 1,000 single-gene-deletion mouse lines, and confirmation of the same cell populations and effector genes in adult human bone. It is curated as EMERGING rather than CANONICAL because the causal demonstrations are in mouse and zebrafish, and no human disorder has yet been shown to produce low bone mass through a demonstrated bone-vascular lesion. Edges belonging to this group carry hypothesis_groups endosteal_vascular_niche_model; a conforming disorder entry should copy the grouping only if its own vascular causal claim belongs to this model.
Do endothelial and vascular smooth muscle lesions in the endosteal compartment cause low bone mass in humans, or do the vascular gene programs score as skeletally relevant because they share genes with the osteoblast lineage?
KNOWLEDGE GAP
OPEN
endosteal_vascular_arm_causal_status
Attached to:
Endosteal Vascular Niche Dysfunction
The enrichment signal that motivates this arm is not uniform across analyses, and the discrepancies point the same way. In the rare-disorder gene enrichment, endothelial and vascular smooth muscle programs reached only nominal significance and the authors themselves attribute that to genes shared with osteoblasts. In the mouse abnormal-bone-structure enrichment, vascular smooth muscle cells were highly enriched but endothelial cells were not. So the two vascular cell types are not equally supported, and the endothelial arm in particular rests on the bone mineral density GWAS enrichment plus single-gene knockouts rather than on monogenic human disease genes. Curators should not upgrade this arm to CANONICAL, and should not let a conforming disorder entry assert a vascular cause of low bone mass on the strength of this module alone.
Proposed experiments:
Endothelial- and VSMC-restricted conditional deletion of validated effector genes
Human bone vascular phenotyping in PLS3-related X-linked osteoporosis
How far does a single-cell map of the mouse endosteal compartment, and functional validation in mouse and zebrafish, transfer to the human endosteal niche?
HUMAN MODEL MISMATCH
OPEN
endosteal_map_species_mismatch
Attached to:
Endosteal Vascular Niche Dysfunction
The cell map and every causal experiment behind this arm are murine or zebrafish; the human component is a bone mineral density GWAS and a single-cell survey of adult human femoral bone. The mouse route was chosen precisely because human endosteal cells are hard to obtain, so the human reference tissue is not equivalent - it is adult femoral head bone from a surgical population, not the metaphyseal and diaphyseal endosteum that was dissected in mouse. The correspondence that was demonstrated is at the level of cell populations and gene expression, which is weaker than a demonstration that the same causal chain operates. This is recorded as HUMAN_MODEL_MISMATCH rather than KNOWLEDGE_GAP because the evidence exists and is strong in the model system; what is open is its translational validity.
Proposed experiments:
Single-cell profiling of the human endosteal compartment
Endosteal Vascular Niche Dysfunction
trigger
The endosteal compartment, at the interface between bone and bone marrow, is the site where bone turnover is regulated, and it contains vascular endothelial cells (sinusoidal, arteriolar and type H) and vascular smooth muscle cells and pericytes alongside the osteoblast, chondrocyte and osteoclast lineages. Cross-species single-cell mapping of this compartment prioritized endothelial cells and vascular smooth muscle cells as skeletal-disease-relevant cell types whose gene programs are enriched for genes associated with estimated bone mineral density, and predicted that they can signal directly to osteoblast lineage cells. Under this emerging model, a lesion in the endosteal vasculature is an upstream driver of remodeling imbalance in its own right, parallel to the hormonal, pharmacological and osteoblast-intrinsic genetic drivers that dominate the rest of this module.
Downstream
-
Bone Remodeling Imbalance
A vascular lesion in the endosteal niche is proposed to act upstream of the remodeling cycle, shifting the resorption/formation balance without an osteoblast- or osteoclast-intrinsic primary defect.
-
Impaired Osteoblastic Bone Formation
Endothelial and vascular smooth muscle cells are predicted to signal directly to osteoblast lineage cells (NOTCH with endothelium, IGF1R with smooth muscle, TGF-beta in common), so loss of that input would be the most direct route from a vascular lesion to a deficient formation arm. The interaction itself is in-silico (CellPhoneDB) and has not been confirmed by a wet-lab ligand-receptor experiment.
Bone Remodeling Imbalance
trigger
The bone remodeling cycle normally tightly couples osteoclastic resorption to osteoblastic formation within the basic multicellular unit, governed by the RANK/RANKL/osteoprotegerin and canonical Wnt signaling axes. The initiating lesion of osteoporosis is disruption of this coupling so that the resorption and formation arms are no longer balanced, regardless of whether the upstream driver is hormonal, pharmacological, or genetic.
Downstream
-
RANKL-Driven Osteoclastogenesis
RANKL-Driven Osteoclastogenesis
amplifier
Loss of remodeling coupling shifts the RANKL/OPG ratio toward RANKL, the critical uncoupling factor that drives differentiation and survival of osteoclasts from myeloid precursors. Estrogen deficiency raises RANKL and lowers OPG; glucocorticoid excess likewise enhances RANKL and suppresses OPG, converging on enhanced osteoclastogenesis.
Downstream
-
Increased Osteoclastic Bone Resorption
Increased Osteoclastic Bone Resorption
central effector
Expanded and activated osteoclasts digest mineralized bone matrix at a rate that exceeds osteoblastic replacement. This is the central effector step of the module: resorption that is normally balanced by an equal wave of formation now outpaces it, eroding trabecular and cortical bone.
Downstream
-
Impaired Osteoblastic Bone Formation
Net Bone Loss and Skeletal Fragility
consequence
Sustained imbalance between excess resorption and deficient formation produces net negative bone balance, loss of bone mineral density, and deterioration of trabecular and cortical microarchitecture. The accumulated structural deficit reduces bone strength and predisposes to low-trauma fractures, the defining clinical consequence of osteoporosis.